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To explore the humanTcell response to acute viral in-
fection, we performed a longitudinal analysis of CD8+
T cells responding to the live yellow fever virus and
smallpox vaccines—two highly successful human
vaccines. Our results show that both vaccines gener-
ated a brisk primary effector CD8+ T cell response of
substantial magnitude that could be readily quanti-
tated with a simple set of four phenotypic markers.
Secondly, the vaccine-induced T cell response was
highly specific with minimal bystander effects.
Thirdly, virus-specific CD8+ T cells passed through
an obligate effector phase, contracted more than
90% and gradually differentiated into long-lived
memory cells. Finally, thesememory cellswere highly
functional and underwent a memory differentiation
program distinct from that described for human
CD8+ T cells specific for persistent viruses. These re-
sults provide a benchmark for CD8+ T cell responses
induced by two of the most effective vaccines ever
developed.
INTRODUCTION
Our understanding of primary antiviral CD8+ T cell responses to
acute viral infections is largely based on experimental studies in
mice. For example, infection of mice with lymphocytic choriome-
ningitis virus (LCMV) or vaccinia virus (VV) inducesmassive CD8+ T
cell activation and expansion, such that 30%–80% of all splenic
CD8+ T cells are virus-specific at 8 days after infection (Butz
and Bevan, 1998; Harrington et al., 2002; Lukacher et al.,
1999; Murali-Krishna et al., 1998). At the peak of the response,
effector CD8+ T cells exhibit an activated phenotype, proliferate,
produce interferon g (IFN-g) in response to antigen, and are
highly susceptible to apoptosis (Butz and Bevan, 1998; Grayson
et al., 2000; Lukacher et al., 1999; Murali-Krishna et al., 1998).
The virus-specific CD8+ T cell pool contracts after viral clear-
ance, with the remaining cells differentiating into long-lived
memory T cells (Murali-Krishna et al., 1998). Long-term mainte-
nance of these cells is antigen independent (Crotty et al., 2003;
Demkowicz et al., 1996; Hammarlund et al., 2003; Lau et al.,710 Immunity 28, 710–722, May 2008 ª2008 Elsevier Inc.1994; Murali-Krishna et al., 1999) and relies on interleukin 7 (IL-
7)- and IL-15-driven homeostatic proliferation (Becker et al.,
2002; Ku et al., 2000; Schluns et al., 2000; Tan et al., 2002;
Wherry et al., 2002). In contrast, chronic infection dramatically
changes the differentiation pathways of virus-specific CD8+ T
cells, often resulting in altered T cell immunodominance, pheno-
type, migration, and function (Barber et al., 2006; Fuller and Za-
jac, 2003; van der Most et al., 2003; Wherry et al., 2004; Wherry
et al., 2003a; Zajac et al., 1998).
To date, human antiviral CD8+ T cell responses have been ex-
tensively analyzed in the context of chronic infections, such as
human immunodeficiency virus (HIV), cytomegalovirus (CMV),
hepatitis C virus (HCV), and Epstein-Barr virus (EBV) (Barouch
and Letvin, 2001; Callan et al., 1998; Hamann et al., 1997; Lauer
et al., 2002; Lechner et al., 2000; McMichael and Rowland-Jones,
2001; Roos et al., 2000; Tan et al., 1999; Urbani et al., 2002; van
Leeuwen et al., 2002). Such responses can be very robust, as ex-
emplified by the massive clonal expansion of antigen-specific
CD8+ T cells in acute infectious mononucleosis (Callan et al.,
1998; Roos et al., 2000; Tan et al., 1999). Based on these studies,
it has also become clear that the resulting populations of human
CD8+ T cells display striking phenotypic differences, as deter-
mined by the expression profiles of surface markers like
CD45RA, CD45RO, CD27, CD28, CCR7, and CD62L (Appay
et al., 2002; Champagne et al., 2001; Sallusto et al., 1999; To-
miyama et al., 2004; van Leeuwen et al., 2002). For example, ef-
fector and central memory CD8+ T cells were defined on the basis
of CD45RA and CCR7 expression patterns (Sallusto et al., 1999),
leading to the following proposed differentiation scheme:
CD45RA+CCR7+ (naive) / CD45RA CCR7+ (central memory
T cells [TCM])/ CD45RA
 CCR7 (effector memory T cells
[TEM]) / CD45RA
+CCR7 (CD45RA+ effector memory T cells
[TEMRA]) (Champagne et al., 2001). This differentiation scheme
is complicated by the observation that different phenotypic sub-
sets of CD8+ T cells accumulate in different chronic infections
(Appay et al., 2002). For instance, terminally differentiated
CD45RA+CCR7 CD8+ T cells dominate the response in persis-
tent CMV infection (Appay et al., 2002; Roos et al., 2000; van
Leeuwen et al., 2002), whereas memory responses in HIV-
infected individuals are dominated by intermediate effector
memory cells (CD45RA CD27+CD28CCR7) (Appay et al.,
2002). Altogether, these studies imply that viral persistence,
whether chronic or latent, has a distinct impact on the differenti-
ation pathways of antiviral CD8+ T cells.
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differentiation (Appay et al., 2002) stresses the need for longitu-
dinal analyses of antiviral T cell responses after acute viral infec-
tion in humans. Live-attenuated viral vaccines provide a potential
model for acute viral infections. Two of the most effective vac-
cines known to medicine, the smallpox vaccine (Dryvax) and
the yellow fever virus (YFV)-17D vaccine are live viruses that re-
sult in acute infections. Indeed, immunization with either vaccine
results in viral replication and long-term protective immunity
(Demkowicz and Ennis, 1993; Demkowicz et al., 1996; Littaua
et al., 1992; McCarthy et al., 1958; Moss, 1999). The YFV-17D
vaccine strain was isolated after consecutive passages in pri-
mary chicken embryo fibroblasts. Immunization results in
a self-limiting viral infection and long-lived neutralizing antibody
titers, i.e., neutralizing antibodies can persist for up to 30–35
years after vaccination (Poland et al., 1981). However, crucial
parameters, such as the kinetics, magnitude, and specificity of
the T cell response, remain largely unknown (Reinhardt et al.,
1998), despite recently mapped HLA-B35 restricted epitopes
(Co et al., 2002). The Dryvax smallpox vaccine contains live vac-
cinia virus (VV) isolated from the lymph of calves infected with the
New York City Board of Health strain of VV (Wyeth, 2002). Neu-
tralizing antibodies are detected in the blood at approximately
10 days after Dryvax immunization (McCarthy et al., 1958).
VV-specific CD4+ and CD8+ effector T cells can be identified by
antigen-stimulation assays at frequencies ranging from 0.1 to
1.1% of CD4+ T cells and 0.4 to 3.7% of CD8+ T cells at 2 weeks
after primary vaccination (Amara et al., 2004). Consistent with
their effector function, these cells express perforin and granzyme
B (Rock et al., 2005). After the peak of the response, a long-lived
pool of memory CD8+ T cells is formed (Demkowicz et al., 1996)
that expresses the IL-7 receptor (CD127) (Rock et al., 2006) and
slowly diminishes over several decades (Crotty et al., 2003;
Hammarlund et al., 2003).
Both vaccines offer the unique opportunity to investigate pri-
mary antiviral T cell responses after acute viral infection in the
absence of antigenic re-exposure. Yellow fever virus is no longer
endemic in the United States, and immunization with YFV-17D is
now limited to visitors to high-risk areas and is not included in
childhood vaccination programs in the Unites States. Similarly,
the last reported case of smallpox occurred in 1978, and there
is no known reservoir for the virus. Furthermore, with the excep-
tion of laboratory and some healthcare workers and military
personnel, smallpox vaccination in the United States was dis-
continued in 1972.
In the present study, we used both these vaccines as models
of acute viral infection in humans. We show that antiviral CD8+ T
cell responses occur rapidly, peaking around 2 weeks after im-
munization. At the peak of the response, up to 12.5% and 40%
of peripheral CD8+ T cells displayed an activated phenotype
(CD38+, HLA-DR +, Ki-67 +, Bcl-2low) after immunization with
YF-Vax and Dryvax, respectively, with no detectable evidence
of bystander activation. Phenotypic analysis of VV-specific
CD8+ T cells revealed that all effector T cells expressed perforin
and granzyme B at the peak of the response. The contraction
and memory phase of the response was associated with further
differentiation of VV-specific T cells. Altogether, our data support
a model of human CD8+ T cell differentiation in which naive CD8+
T cells undergo massive expansion in response to antigen andpass through an effector phase prior to gradually differentiating
into long-lived memory cells.
RESULTS
Identifying YF-Vax- and Dryvax-Induced Effector CD8+ T
Cells by Phenotypic Analysis
To test the notion that the human CD8+ T cell response to acute
viral infection would be associated with an emerging population
of activated effector cells, we analyzed the expression patterns
of a large set of surface and intracellular markers on CD8+ T cells
after immunization with the live-attenuated YFV (YF-Vax) or Dry-
vax smallpox vaccine. Although many markers displayed
changed expression patterns after immunization, we found that
only a small subset of phenotypic markers (CD38, HLA-DR, Ki-
67, and Bcl-2) had sufficiently low preimmunization background
expression to allow the unequivocal identification of the expand-
ing populations of activated CD8+ T cells. The emergence of
a phenotypically discrete pool of effector T cells was subse-
quently confirmed by functional analyses and major histocom-
patibility complex (MHC) class I tetramer staining (see below).
HLA-DR and CD38 are well-described differentiation markers
that are expressed by activated T cells during the acute phase
of chronic and persistent viral infections in humans (Appay
et al., 2002; Callan et al., 1998; Lechner et al., 2000). Analyzing
the HLA-DR and CD38 expression patterns on peripheral CD3+
CD8+ peripheral blood mononuclear cells (PBMCs) at multiple
time points after immunization allowed us to evaluate the magni-
tude and kinetics of the T cell responses after immunization. In
both the YF-Vax and Dryvax immunization trials, we observed
baseline expression of 0.5%–2% of CD38+ HLA-DR+ CD8+ T cells
in the PBMCs prior to vaccination (Figure 1A). After YF-Vax immu-
nization, a substantial expansion of activated CD38+ HLA-DR+
CD8+ T cells was detected in all vaccine recipients. This response
wasassociated witha transient viremia. Viral RNA wasdetected in
plasma at days 3 and 7 after immunization, peaking at day 7
(Figure 1A). The peak of the CD8+ T cell response was observed
at day 15 after immunization, when 4%–13% of peripheral CD8+
T cells coexpressed CD38 and HLA-DR (Figure 1A). This percent-
age declined sharply in all volunteers by day 30 after immunization
and remained at background levels during the memory phase of
the T cell response. Even greater expansions of activated CD8+
T cells were observed after Dryvax immunization (Figure 1B). At
the peak of the response (day 14), 10%–40% of peripheral
CD8+ T cells expressed an activated phenotype. Similar to the
YF-Vax-induced response, numbers of activated CD8+ T cell
declined after day 15, returning to baseline by day 30 after
immunization.
To further characterize the effector T cell response induced by
immunization, we measured expression of the proliferation
marker Ki-67 (Gerdes et al., 1984) and the antiapoptotic protein
Bcl-2 (Hockenbery et al., 1990) in CD8+ T cells. Resting T cells do
not express Ki-67, whereas cycling or recently divided T cells up-
regulate Ki-67 expression (Chakrabarti et al., 2000; Gerdes et al.,
1984; Pitcher et al., 2002). Bcl-2 is a useful marker because its
downregulation indicates susceptibility to apoptosis (Appay
et al., 2002; Grayson et al., 2000). Indeed, over 99% of peripheral
CD8+ T cells exhibited a resting Ki-67- Bcl-2high phenotype be-
fore immunization, with less than 0.5% of CD8+ T cells displayingImmunity 28, 710–722, May 2008 ª2008 Elsevier Inc. 711
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Human Memory CD8+ T Cell Differentiationthe activated Ki-67+ Bcl-2low phenotype (Figure 2A). The propor-
tion of Ki-67+ Bcl-2low CD8+ T cells increased sharply after immu-
nization. At the peak of the YF-vax response, 3%–11% of CD8+ T
cells were Ki-67+, Bcl-2low. Similarly, 10%–40% of CD8+ T cells
were Ki-67+, Bcl-2low at the peak of the T cell response to Dryvax
immunization. In both cases, percentages of activated CD8+ T
cells declined rapidly to background by day 30 after infection
(Figure 2B).
The expression kinetics of Ki-67 and Bcl-2 on CD8+ T cells mir-
rored those of CD38 and HLA-DR. Indeed, we found that CD38+
CD8+ T cells were Ki-67+ and Bcl-2low, indicating that the combi-
nation of these markers effectively identified a recently gener-
ated population of activated T cells (Figure S1A available online).
Because staining with these markers clearly identified an effec-
tor CD8+ T cell population, it also allowed us to analyze the
expression patterns of other phenotypic markers on these acti-
vated CD8+ T cells. This led to a provisional phenotypic definition
of effector cells as granzyme Bhigh, CCR5high, CCR7low,
CD45RAlow, and CD62Lint (Figure S1B). Thus, immunization
Figure 1. Identification of Activated CD8+ T Cells after Vaccination
CD38 and HLA-DR expression on CD8+ T cells after YF-Vax (A) or Dryvax (B)
immunization. Heparinized whole-blood samples from vaccine recipients were
stained with antibodies against CD3, CD8, CD38, and HLA-DR. FACS contour
plots were gated on CD3+, CD8+ cells. YFV in the blood was quantitated by
a real-time PCR. Error bars represent the standard error of the mean for three
volunteers.712 Immunity 28, 710–722, May 2008 ª2008 Elsevier Inc.with the YF-Vax and Dryvax vaccines induced massive expan-
sions of activated CD38+ HLA-DR+ Ki-67+ Bcl-2low CD8+ T cells.
Dryvax immunization resulted in a 3- to 4-fold larger response
than did YF-Vax immunization. However, the kinetics of the
YF-Vax- and Dryvax-induced responses were similar. Activated
CD8+ T cells were Ki-67+, consistent with massive expansion,
and were susceptible to undergo apoptosis (Bcl-2low), consistent
with the subsequent contraction phase of the response. Al-
though the main conclusion from these experiments is that
CD8+ T cell responses against live-attenuated vaccines are
very large in magnitude, our data also illustrate that simple
combinations of six markers (CD3, CD8, CD38, HLA-DR, Ki-67,
and Bcl-2) can be used to identify effector T cell responses after
immunization or infection.
Functional Characterization of Vaccine-Induced
CD8+ T Cells
To correlate the observed expansions of activated CD8+ T
cells with antigen-specific responses, we used intracellular
Figure 2. Identification of Proliferating and Proapoptotic CD8+ T
Cells after Vaccination
Ki-67 and Bcl-2 expression in CD8+ T cells after YF-Vax (A) or Dryvax (B)
immunization. Heparinized whole-blood samples from vaccine recipients
were stained with antibodies against CD3, CD8, permeabilized, and subse-
quently stained for intracellular Ki-67 and Bcl-2 expression. FACS contour
plots were gated on CD3+, CD8+ cells.
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tion. YFV-specific responses were visualized by stimulation of
PBMCs with YFV-infected SW-480 cells. The HLA-A2 allele
was the only confirmed match between the stimulator cell line
and the YF-Vax vaccine recipients. Thus, this assay measured
at least the HLA-A2-restricted component of the total response.
To assess VV-specific responses after Dryvax immunization, we
infected PBMCs from vaccine recipients overnight with VV virus.
Thus, whereas the YFV-stimulation assay only measured the
HLA-A2-restricted fraction of the total response, the VV-stimula-
tion assay was not restricted by HLA type.
YFV-specific CD8+ T cell responses were first identified by in-
tracellular IFN-g staining at day 7 after immunization and peaked
at day 14, when 0.5%–3% of all CD8+ T cells secreted IFN-g
upon stimulation (Figure 3A). We observed a strong correlation
between the frequency of IFN-g-producing cells and the number
of CD38+, HLA-DR+, Ki-67+, Bcl-2low CD8+ T cells (r2 = 0.62 for
IFN-g+ versus CD38+ HLA-DR+ and r2 = 0.67 for IFN-g+ versus
Ki-67+ Bcl-2low) (Figure S2A). To estimate the total YFV specific
response, we stimulated PBMCs from vaccinated volunteers
with matrix pools of overlapping 15-mer peptides that spanned
the entire YFV polyprotein. An estimate of the total YFV-specific
CD8+ T cell response was approximated by addition of the per-
centage of IFN-g+ CD8+ cells in the 36 peptide pools that con-
tained consecutive peptides. This analysis revealed that 2
months after vaccination, 0.1%–1.5% of CD8+ T cells were spe-
cific for YFV (Figure 3B). Frequencies of YFV-specific T cells
slowly declined thereafter but were still detectable at frequencies
ranging from 200–600 IFN-g secreting cells per 106 PBMCs at 1
year after immunization (data not shown). We also observed
a correlation between the peak expression of Ki-67+ CD8+ T cells
at day 15 and the level of long-term YF-Vax-specific memory.
The VV-specific response kinetics were similar to the YFV re-
sponse kinetics. By day 14 after vaccination, between 3% and
14% of CD8+ T cells produced IFN-g upon VV stimulation
(Figure 3C). VV-specific IFN-g-producing cells were still de-
tected at day 84 after immunization. As observed for YF-Vax,
we found strong correlations between IFN-g-producing cells
and the frequencies of activated cells identified by CD38, HLA-
DR, Ki-67, and Bcl-2 staining (r2 = 0.88 for IFN-g+ versus
CD38+ HLA-DR+ and r2 = 0.91 for IFN-g+ versus Ki-67+ Bcl-
2low) (Figure S2B). We did not detect intracellular tumor necrosis
factor a (TNF-a) in the majority of IFN-g-producing T cells. A pos-
sible explanation for this is that TNF-a production is not sus-
tained during the 20 hr stimulation assay, in contrast to IFN-g
production (Slifka et al., 1999). Indeed, 6 hr stimulation of PBMCs
with VV peptides (Terajima et al., 2003) generated primarily IFN-g
TNF-a double-positive CD8+ T cells (data not shown).
The kinetics of antigen-specific CD8+ T cell responses di-
verged from those visualized by the expression of activation
markers in two respects. First, antigen-specific CD8+ T cells
were detected beyond day 30 after immunization, whereas the
proportion of activated effector CD8+ T cells (CD38+, HLA-
DR+, Ki-67+, Bcl-2low) had returned to baseline levels at that
point. This suggests that antigen-specific effector CD8+ T cells
had lost their activated phenotype and differentiated into mem-
ory cells. Second, although the percentages of IFN-g-producing
CD8+ T cells strongly correlated with the percentages of CD38+,
HLA-DR+ and Ki-67+, Bcl-2low CD8+ T cells at the peak of theresponse (Figures 1–3), they were consistently lower. The mag-
nitude of the VV-specific CD8+ T cell response based on the
IFN-g assay accounted for approximately one-third of the total
number of activated CD8+ T cells as determined by phenotypic
analysis. The fact that the VV life cycle is blocked at an early
stage in antigen-presenting cells (APCs) provides a potential ex-
planation as it predicts that our assay will preferentially detect T
cells specific for early antigens (Chahroudi et al., 2006). Indeed,
a population of CD8+ T cells specific for an HLA-A2-restricted
epitope in the putative early and late 189R gene open reading
frame (Terajima et al., 2003) failed to produce IFN-g after over-
night VV stimulation (data not shown). However, it is possible
that acute viral infections elicit a large population of bystander
activated CD8+ T cells or that not all VV-specific T cells can
produce cytokines in response to antigen stimulation.
Figure 3. Kinetics of the YFV- and VV-Specific CD8+ T Cell
Responses
(A) PBMCs from YFV-immunized donors, stimulated with YFV-infected
SW-480 cells and analyzed for IFN-g-producing cells.
(B) IFN-g-producing CD8+ T cells in PBMCs from nine donors immunized
60 days before, stimulated with overlapping peptides spanning the YFV
polyprotein. Error bars represent the standard error of the mean for three
volunteers.
(C) PBMCs from Dryvax immunized donors stimulated with VV and analyzed
for cytokine production.
(D) Percent of CD8+ T cells that produce IFN-g in response to VV stimulation.Immunity 28, 710–722, May 2008 ª2008 Elsevier Inc. 713
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or Dryvax Immunization
To evaluate possible CD8+ T cell bystander activation during
acute viral infection, we analyzed how pre-existing nonvac-
cine-specific memory CD8+ T cells responded to immunization.
Therefore, we monitored the activation status of the EBV-, CMV-,
and/or influenza virus-specific CD8+ T cell populations that were
present in multiple vaccine recipients. Responses of these unre-
lated memory CD8+ T cells after Dryvax and YF-Vax immuniza-
tion were evaluated by analysis of the expression patterns of
CD38, Ki67, and CD62L on unrelated memory CD8+ T cells, iden-
tified by MHC class I tetramer staining.
As shown in Figure 4A, we found that EBV-specific tetramer+
CD8+ T cells (HLA-A2 EBVRAK) were neither activated nor prolif-
erating (as defined by CD38 and Ki-67 upregulation, respec-
tively) in response to YF-Vax immunization. However, in the
same individual, we observed activated and proliferating CD8+
T cells in the tetramer-negative population, providing evidence
of a strong YF-Vax induced response. Identical results were ob-
tained with a CMV-specific tetramer (data not shown). Similarly,
influenza virus (HLA-A2 INFGIL)-specific T cells in Dryvax-immu-
nized volunteers did not upregulate CD38 or Ki-67 at any time af-
ter immunization (Figure 4B). In contrast, VV-specific CD8+ T
cells (comprised within the tetramer-negative population) in the
same individual dramatically upregulated CD38 and Ki-67 by
day 15 after immunization (Figure 4B). Thus, we found no evi-
dence for activation or for a proliferative response of unrelated
CD8+ T cells after Dryvax or YF-Vax immunization. This suggests
that bystander CD8+ T cell proliferation did not contribute to the
massive expansion of effector T cells observed after vaccination.
In order to further determine the phenotypic nature of the EBV
and influenza virus specific CD8+ T cell memory pools (i.e., effec-
tor or central memory) in immunized individuals, we also ana-
lyzed CD62L expression on tetramer+ EBV- and influenza
virus-specific CD8+ T cells. This revealed that the EBV-specific
memory CD8+ T cell pool predominantly consisted of CD62Llow
effector memory cells (76%) but also harbored CD62Lhigh central
memory cells (Figure 4A). The influenza virus-specific CD8+
memory T cell pool consisted almost exclusively of CD62Lhigh
central memory cells (Figure 4B). Because none of these mem-
ory cell populations displayed any bystander activation, our
data imply that neither unrelated effector nor central memory
cells were activated in a bystander fashion after YF-Vax or
Dryvax immunization.
Combined, these results show that bystander activation of
memory CD8+ T cells plays at most a limited role and does not
contribute to the peak of the CD8+ T effector cell response after
immunization. Thus, it is very likely that the observed effector
CD8+ T cell responses to YF-Vax and Dryvax are mostly antigen
specific.
Tracking VV-Specific CD8+ T Cell Responses with MHC
Class I Tetramer
We used an MHC class I tetramer specific for an HLA-A2-re-
stricted VV epitope, CLTEYILWV (Terajima et al., 2003), to further
characterize the dynamics of the response and the phenotype of
VV-specific effector and memory CD8+ T cells. HLA-A2 VVCLT
tetramer+ CD8+ T cells were detected in all 5 HLA-A2+ donors,
ranging from 0.2% to 0.5% of total CD8+ T cells at the peak of714 Immunity 28, 710–722, May 2008 ª2008 Elsevier Inc.the response (Figure 5A). The kinetics of HLA-A2 VVCLT+ CD8+
T cells (Figure 5B) were similar to the kinetics of activated
(CD38+ HLA-DR+ Ki-67+ Bcl-2low) CD8+ T cells (Figure 3) and
VV-specific IFN-g-producing CD8+ T cells (Figure 3). This pro-
vides further evidence that the quantification of CD8+ T cell acti-
vation with this set of markers accurately predicts kinetics of the
CD8+ T cell response to acute infection. The HLA-A2 VVCLT
Figure 4. Analysis of Bystander CD8+ T Cell Activation after YF-VAX
or Dryvax Vaccination
Heparinized whole-blood samples from YFV- and VV-immunized volunteers
were stained with HLA-B8 EBVRAK (A) or HLA-A2 INFGIL (B) tetramers and
antibodies against CD8, CD38, CD62L, and Ki-67. FACS plots are gated on
CD8+ T cells.
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by MHC Class I Tetramer
(A) PBMCs from volunteers immunized with the smallpox
vaccine were stained with HLA-A2 VVCLT tetramer and
antibodies against CD3 and CD8.
(B) The percentage of HLA-A2 VVCLT tetramer-specific CD8+ T
cells as a proportion of total CD8+ T cells were plotted over
time for five vaccinated volunteers.
(C and D) HLA-A2 VVCLT tetramer-specific effector and mem-
ory CD8+ T cells at day 15 (C) and 6 months (D) after VV immu-
nization were analyzed for the expression of various pheno-
typic markers. Antigen-specific CD8+ T cells are depicted as
red dots and total CD8+ T cells as the gray background.
(E) Gradual effector-to-memory transition of VV antigen-
specific cells after vaccination. Heparinized whole-blood
was stained at multiple time points after smallpox vaccination
with antibodies against Ki-67, granzyme B, CD45RA, CCR5,
CD3, and CD8 and HLA-A2 VVCLT tetramer. The plots shown
are gated on CD8+ T cells.Immunity 28, 710–722, May 2008 ª2008 Elsevier Inc. 715
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specific effector (Figure 5C) and memory (Figure 5D) CD8+ T
cells.
At day 15 after immunization, HLA-A2 VVCLT tetramer staining
revealed a population of activated CD45RO+ CD8+ T cells char-
acterized by the upregulation of CD38, CD27, HLA-DR, Ki-67,
CCR5, perforin, and granzyme B and downregulation of Bcl-2,
CCR7, and CD127 (Figure 5C). Consistent with previous data
from mouse infection models, effector CD8+ T cells also ex-
pressed Programmed Death 1 (PD-1). Surprisingly however, tet-
ramer+ effector CD8+ T cells were also CD62Lint. These findings
are consistent with the effector T cell phenotype deduced from
bulk T cell staining after YF-Vax immunization (Figure S1). Ex-
pression of perforin and granzyme B, hallmarks of effector T
cells, indicates that all tetramer+ CD8+ T cells possess high
cytolytic potential at the peak of the effector T cell response.
By using the VVCLT tetramer, we then analyzed the phenotype
of VV-specific memory CD8+ T cells. Six months after Dryvax im-
munization, we detected HLA-A2 VVCLT-specific T cells at 0.03%
of total CD8+ T cells (Figure 5D). At this point, most antigen-spe-
cific cells had undergone further differentiation and no longer ex-
hibited an effector phenotype (Figure 5D). Tetramer+ memory
HLA-A2 VVCLT+ T cells were CD45RA+ and CD27+, had downre-
gulated CD38, HLA-DR, and Ki-67, and re-expressed Bcl-2 and
CD127. Bimodal expression patterns were observed for CCR5,
CCR7, CD62L, CD28, and granzyme B. Memory CD8+ T cells
had downregulated PD-1 expression, consistent with their full
functionality and clearance of virus (Figure 5D). This result sug-
gests that antigen stimulation is required to maintain PD-1 ex-
pression on memory CD8+ T cells. The phenotype that we de-
scribe here was observed in all donors that possessed HLA-A2
VVCLT-specific T cells (n = 5). The bimodal expression patterns
of granzyme B, CCR5, CCR7, CD62L, and CD28 suggest that
memory T cell populations may be further subdivided on the ba-
sis of their homing marker expression and cytotoxic potential.
Effector-to-Memory CD8+ T Cell Transition
after Vaccination
On the basis of the distinct phenotypes of effector and memory
CD8+ T cells, we asked whether the transition from an effector to
a memory cell phenotype would be an abrupt or gradual event
and whether this transition would occur simultaneously for differ-
ent markers. To address this question, we analyzed the expres-
sion patterns of a selected set of markers (Ki-67, CD45RA,
CCR5, and granzyme B) on tetramer+ CD8+ T cells at multiple
time points after immunization (days 15, 21, 28, and 84). As
shown in Figure 5E, differentiation from effector to memory phe-
notype happened gradually over several weeks of time. Interest-
ingly, effector-to-memory transition did not progress simulta-
neously for all markers. For instance, Ki-67 downregulation
was an early event with most tetramer+ cells downregulating
Ki-67 expression by day 21 after immunization. In contrast, the
change from CD45RO to CD45RA and the downregulation of
granzyme B occurred with slower kinetics. Thus, tetramer+ T
cells displayed effector-like expression of granzyme B and
CD45RA at 28 days after infection but were no longer proliferat-
ing (Ki-67) and displayed different migration properties (CCR5).
Combined, these data suggest that antigen-specific CD8+ T
cells pass through several phenotypic stages after the peak of716 Immunity 28, 710–722, May 2008 ª2008 Elsevier Inc.the effector response. However, the nonsimultaneous, gradual
changes in the expression patterns of several key markers
suggest that effector-to-memory CD8+ T cell differentiation is
a continuous, linear process and not a succession of discrete
phenotypic stages.
At 2 years after immunization, CD45RA+ tetramer+ CD8+ T
cells were still detectable in the blood at a frequency of
0.012% of CD8+ T cells (data not shown). Expression of
CD45RA has been proposed as a surrogate marker for terminally
differentiated memory CD8+ T cells, with limited proliferative
potential (Champagne et al., 2001). To test whether this pheno-
type applied to VV-specific CD45RA memory cells, we stimu-
lated 5,6-carboxy fluorescein diacetate succinimidyl ester
(CFSE)-labeled PBMCs with the VVCLT peptide. Clearly, after 6
days of stimulation with peptide, HLA-A2 VVCLT+ T cells under-
went multiple rounds of proliferation (Figure 6A). CD45RA mem-
ory cells also produced IFN-g and IL-2 after 6 hr peptide stimu-
lation (Figure 6B). These results suggest that CD45RA+ memory
T cells are not terminally differentiated and maintain the potential
to proliferate and secrete effector cytokines in response to anti-
gen. Similar results were obtained when PBMCs from YF-Vax
immunized volunteers were stimulated with a pool of five pep-
tides (Co et al., 2002): YFV-specific CD8+ T cells displayed ex-
tensive proliferation (Figure 6A) and produced IFN-g and IL-2
upon antigenic stimulation (Figure 6B).
CD4+ T Cell and B Cell Responses
after Drvax Vaccination
In order to determine how the VV-specific CD8+ T cell response
relates to the other major components of the adaptive immune
system, the VV-specific CD4+ T cell response and the neutraliz-
ing antibody titer were compared in the same subjects (Figure 7).
VV-neutralizing antibodies were detected by day 15 after vacci-
nation and were maintained at high levels. The magnitude of the
VV-specific CD4+ T cell response was measured by IFN-g pro-
duction in response to vaccinia virus stimulation of donor
PBMCs in vitro. The kinetics of the CD4+ T cell response paral-
leled the VV-specific CD8+ T cell response. However, it was
one-half to one-third of the magnitude of the VV-specific CD8
T cell response. It is worth noting that the ratio of virus-specific
CD8 versus CD4 T cell responses seen in humans after Dryvax
immunization was strikingly similar to the results seen in mice
after VV infection, where the CD8 T cell responses were again
higher in magnitude than the CD4 T cell responses (Harrington
et al., 2002). In summary, the data in Figure 7 show that CD8+
T cell responses after smallpox vaccination occur in concert
with CD4+ T cell and B cell responses and that all of these
primary T and B cell responses occur very rapidly.
DISCUSSION
Longitudinal studies of host immune responses after the onset of
infection are crucial to understanding of the generation and
maintenance of antigen-specific effector and memory T cells in
humans. To explore the human CD8+ T cell response to acute
infection, we performed a longitudinal analysis of CD8+ T cells
responding to the live YFV and smallpox (vaccinia virus)
vaccines—two of the most successful human vaccines ever
developed. Our study makes four distinct points. First, we
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(A) PBMCs from VV- and YFV-vaccinated donors at 2 years or 90 days after vaccination, respectively, were labeled with CFSE and stimulated in the presence or
absence of VVCLT peptide or YFV peptide pools for 6 days. Proliferation was measured by dilution of the CFSE dye as analyzed by flow cytometry. The VV
histogram is gated on HLA-VVCLT tetramer-specific CD8+ T cells. YFV plots are gated on CD3+ CD8+ lymphocytes.
(B) PBMCs from VV- and YFV-vaccinated donors were stimulated in the presence or absence of VVCLT peptide or YFV peptide pools for 6 hr and cells were
stained for intracellular cytokine levels. The data shown are gated on CD3+ CD8+ T cells.show that the expression patterns of the activation markers HLA-
DR, CD38, Ki-67, and Bcl-2 could be used to identify the newly
generated effector CD8+ T cells. This simple phenotypic analysis
should be broadly applicable to quantify effector T cells after im-
munization or infection. Second, both vaccines induced a brisk
primary effector T cell response of substantial magnitude that
was readily detectable within 2 weeks of infection. At the peak
of the primary response, YFV- and VV-induced effector CD8+ T
cells accounted for up to 12.5% and 40% of CD8+ T cells in
the blood, respectively. Third, by monitoring the responses of
pre-existing memory CD8+ T cells to unrelated pathogens, we
show that there was minimal to no bystander activation or prolif-
Figure 7. Kinetics of CD4+ andCD8+ TCell andNeutralizingAntibody
Responses to Dryvax Vaccine
The percentage of IFN-g-producing CD4+ and CD8+ T cells and the VV-
neutralizing antibody titers for a single donor after Dryvax immunization were
plotted over time. These data are representative of responses observed in
other individuals.eration after YFV or VV immunization and that the majority of the
responding T cells are likely to be specific to the vaccine. Fourth,
phenotypic analysis of MHC class I tetramer+ CD8+ T cells indi-
cated that (1) virus-specific CD8+ T cells pass through an obli-
gate effector phase defined by the expression of perforin and
granzyme B, (2) effector T cells contracted to approximately
10% of the peak and then gradually differentiated into a long-
lived pool of memory cells, and (3) memory CD8+ T cells gener-
ated after acute VV or YFV infection exhibited phenotypic and
functional characteristics distinct from those described for
human CD8+ T cells specific for persistent viruses.
We used a combination of four phenotypic markers (CD38,
HLA-DR, Ki-67, and Bcl-2) to identify a discrete population of ac-
tivated effector CD3+ CD8+ T cells. We propose that this popu-
lation truly represents the antigen-specific T cells response.
This implies that simple phenotypic analysis can be used to as-
sess T cell responses without prior knowledge of antigenic spec-
ificity. We predict that with the simultaneous use of four markers
to visualize a single population of T cells, even much weaker re-
sponses can be rapidly visualized. In addition, these markers can
be utilized during vaccine trials to more specifically determine
the quality of CD8+ priming and differentiation.
The magnitude of antiviral CD8+ T cell response, as estimated
by phenotypic analysis, ranged from 2% to 13% for YF-Vax and
10% to 40% of CD8+ T cells for Dryvax at the peak of the T cell
response. Functional analyses (IFN-g staining) could account for
only one-third of the total response, but this probably reflects
limitations of the stimulation protocols that we used. It is also
possible that not all virus-specific CD8+ T cells respond byImmunity 28, 710–722, May 2008 ª2008 Elsevier Inc. 717
Immunity
Human Memory CD8+ T Cell DifferentiationIFN-g production. Nevertheless, the total numbers of CD8+ T
cells involved in these responses are very high. On the basis of
a total estimated number of 3 3 1011 CD8+ T cells in humans
(Boon et al., 2006), we estimate that at the peak of the response
(2 weeks), between 93 109 and 4.23 1010 CD8+ T cells were VV
specific and between 1.5 3 109 and 9 3 109 CD8+ T cells were
YFV specific, on the basis of IFN-g production. On the basis of
phenotypic staining, the total number of activated CD8+ T cells
could be as much as 1.2 3 1011 cells (40%) and 3.8 3 1010 for
Dryvax and YF-Vax, respectively. Assuming an approximate
precursor frequency of 1/105 to 1/106 naive T cells, this corre-
sponded up to a 104- to 105-fold expansion of IFN-g+ T cells,
or up to 16–20 cell divisions. These results parallel studies in
murine models where CD8+ T cells undergo up to 15 rounds of
proliferation in vivo during an acute viral infection (Murali-Krishna
et al., 1998).
The peak of the CD8+ effector T cell response occurred within
2 weeks after YF-Vax or Dryvax immunization. For both vac-
cines, effector responses declined to background by 4 weeks af-
ter inoculation. Similar kinetics were observed for CD4+ T cells
and neutralizing antibody titers. In contrast, T and B cell re-
sponses to chronic infections (such as HIV, HBV, and HCV)
can take much longer to develop after infection (Forns et al.,
2000; Sakai et al., 2007; Thimme et al., 2002; Thimme et al.,
2003). Thus, our experiments reveal very different response
kinetics in acute versus chronic infection settings. It is tempting
to speculate that the rapid response to Dryvax or YF-Vax immu-
nization represents the optimal response, whereas slower re-
sponses are suboptimal and may be causally related to
viral persistence.
VV-specific tetramer+ cells contracted more than 90% by day
84 after infection. Assuming similar contraction kinetics for all
VV-specific T cells, we estimate that the memory pool at this
time point contained approximately 13 109 VV-specific memory
CD8+ T cells. In the absence of antigen, we detected a further de-
cline in tetramer+ memory cells. From 3 months to 2 years after
infection, we observed an approximately 60% reduction in anti-
gen-specific cells. Assuming that this loss in the memory phase
was constant and linear over time, this means that the size of the
HLA-A2 VVCLT-specific memory population will exceed the size
of the precursor pool for at least 12 years and that tens of thou-
sands of memory cells, capable of immediate recall responses,
will survive over 20 years. In fact, we were able to detect bulk
VV-specific T cells by IFN-g secretion in individuals that were
vaccinated more than 50 years prior (data not shown). This sug-
gests that CD8+ T cell burst size is one of the biological determi-
nants that may be responsible for long-term protective immunity
of the Dryvax and YF-Vax vaccines.
The role of bystander activation during antiviral T cell re-
sponses has been a long-standing and controversial issue
(Butz and Bevan, 1998; Callan et al., 1998; Ehl et al., 1997;
McNally and Welsh, 2002; Murali-Krishna et al., 1998; Tough
et al., 1996; Tough and Sprent, 1998; Zarozinski and Welsh,
1997). Previous studies suggested that nonspecific CD8+ T cells
can display an activated phenotype and perform cytolytic T cell
functions in the apparent absence of T cell receptor (TCR)
engagement (Ehl et al., 1997; Tough et al., 1996). However,
with the advent of MHC tetramer technology, it is now clear
that the massive expansions of effector CD8+ T cells in murine718 Immunity 28, 710–722, May 2008 ª2008 Elsevier Inc.LCMV infections and human EBV infections (infectious mononu-
cleosis) are mostly antigen specific (Callan et al., 1998; Murali-
Krishna et al., 1998; Tan et al., 1999). This suggests that TCR
engagement is the primary driving force behind the activation
of antiviral CD8+ T cells but does not disprove a possible, albeit
small, role for bystander activation. However, by using MHC
class I tetramers for EBV-, CMV-, and influenza-specific CD8+
T cells, we found that unrelated memory CD8+ T cells do not
contribute to the peak of the VV- and YF-Vax-specific CD8+ T
cell response, either by upregulation of activation markers or
by proliferation. Interestingly, we did detect some activation of
EBV-specific CD8+ T cells in vaccine recipients at day 21 after
Dryvax immunization, although influenza-specific CD8+ T cells
in the same individuals did not show any changes in number or
phenotype (data not shown). On the basis of the kinetics and
EBV specificity of this phenomenon, this result likely reflects
the reactivation of latent EBV in response to Dryvax immuniza-
tion (Doisne et al., 2004; Lechner et al., 2000). A similar phenom-
enon was recently described in individuals acutely infected with
Puumala virus (Tuuminen et al., 2007). Combined, these data
suggest that the large populations of effector T cells observed
at the peak of the response are specific for VV or YFV antigens
and that TCR engagement is a prerequisite for activation of anti-
gen-specific CD8+ T cells. This implies that memory CD8+ T cells
are unlikely to be maintained by bystander activation as a result
of a heterologous infection (i.e., without TCR engagement). Thus,
long-term T cell memory appears to be maintained in the
absence of antigenic stimulation, although there is most likely
a slow decline over time.
MHC class I tetramer staining allowed us to define detailed ef-
fector and memory CD8+ T cell phenotypes. Consistent with their
function, effector CD8+ T cells expressed Ki-67 (proliferation),
granzyme B, and perforin (cytolytic activity) and downregulated
Bcl-2 (prone to undergo apoptosis). Transient PD-1 expression
was observed, similar to results from murine infection models.
These data support a model in which primed effector cells exit
lymph nodes by downregulating CCR7, migrate to infected tis-
sues via CCR5, and kill infected cells by secreting perforin and
granzyme. A surprising finding was that the majority of effector
CD8+ T cells were CD62Lint, whereas T cell activation is usually
associated with CD62L downregulation (Callan et al., 1998;
Wherry et al., 2003b). This lack of downregulation did not result
from an intrinsic defect because VV-specific CD62Lhigh CD8+ T
cells rapidly downregulated CD62L upon in vitro restimulation
(data not shown). CD62L downregulation has previously been
described in patients with chronic or persistent infections (Callan
et al., 1998), and it is possible that the lack of CD62L downregu-
lation in our experiments reflects the differences between acute
and chronic viral infections, e.g., antigen load, duration of anti-
gen exposure, and impairment of T cell function in the setting
of chronic antigen exposure.
The effector molecules perforin and granzyme B were ex-
pressed by all HLA-A2CLT tetramer+ CD8+ T cells at the peak of
the response (day 14), consistent with recently published data
(Precopio et al., 2007). This indicates that antiviral CD8+ T cells
pass through an obligate effector phase before differentiating
into memory cells, suggesting a linear effector-to-memory differ-
entiation model. The phenotypic changes that accompanied
passage from the effector to memory phase occurred gradually
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markers. For example, Ki-67 downregulation was an early event,
whereas downregulation of granzyme B and CCR5 happened
more slowly. Also, the transition from effector to memory pheno-
type was associated with a gradual change from CD45RO+ to
CD45RA+ (Carrasco et al., 2006). Thus, whereas effector and
memory cells were strictly CD45RO+ and CD45RA+, respec-
tively, more complex phenotypes existed in the transition phase.
Altogether, these data support a model of linear differentiation
where naive cells expand and differentiate into effector cells after
antigen stimulation and then contract and slowly differentiate
into a stable population of memory cells.
The VV-specific (HLA-A2CLT tetramer+) memory CD8+ T cell
pool itself was phenotypically diverse. Memory cells expressed
CD45RA and CD27 and were characterized by downregulation
of activation markers such as Ki-67, CD38, HLA-DR, and PD-1
and bimodal expression of CCR7, CCR5, CD62L, CD28, and
granzyme B. The bimodal expression patterns of multiple hom-
ing markers suggest that the memory cell population may be
subdivided on the basis of lymphoid and tissue homing capabil-
ities, consistent with the central and effector memory concept.
Memory cells expressed the IL-7 receptor CD127, similar to
HIV- and RSV-specific memory cells and previously reported
VV data, suggesting that IL-7 signaling plays a role in the homeo-
static maintenance of memory populations (Kaech et al., 2003).
At 6 months after immunization, we observed small populations
of CD127low VV-specific CD8+ T cells, possibly representing
memory cells that had recently received IL-7 signals (Vranjkovic
et al., 2007). The memory phenotype that we describe here
seems to differ slightly from the recently described CD45RA+
CD27int VV-specific CD8+ T cells, detected at 1 month after Dry-
vax immunization. According to our data, CD45RO- and
CD45RA-expressing memory T cells coexist at this time. How-
ever, close inspection of the data reported by Precopio et al.
(2007) suggests that CD45RO+ cells were still detected at 1
month after immunization. Combined, these data support our
conclusion that effector-to-memory differentiation is a gradual
and continuous process.
The phenotype of VV-specific memory cells does not entirely
correlate with the current differentiation models proposed for
human memory CD8+ T cells. For example, Champagne et al.
(2001) and Sallusto et al. (1999) have defined CD45RA+ CCR7
CD8+ T cells as terminally differentiated and unable to undergo
substantial proliferation upon antigenic stimulation. This is
clearly different from our present data. The obvious variable
that could explain these differences is that we describe a memory
phenotype in the context of acute rather than chronic infection.
Transient viremia (as observed for YF-Vax) implies that the tran-
sition from effector to memory cells occurs in the absence of an-
tigenic stimulation. In contrast, the effector-to-memory transition
during chronic infection is most likely associated with persistent
TCR stimulation. This difference in the persistence and degree of
TCR signaling may differentially affect the maturation pathway of
responding CD8+ T cells during acute and chronic infections, re-
sulting in distinct cellular phenotypes and functional capacities.
Thus, persistent antigen exposure during the memory-formation
phase could lead to different, and possibly less functional, CD8+
memory T cells. This implies that vaccine boosting should occur
after the formation of a phenotypically stable population ofmemory cells. Furthermore, drug therapies aimed at reducing vi-
ral loads during the early stages of chronic infections may result
in the formation of more effective immune memory.
In conclusion, we report that human CD8+ T cell responses to
acute viral infections are very large and can be visualized in
a nonantigen-specific way by the simple combination of four
activation markers. The collective evidence suggests that the
response identified by these markers is the true antiviral re-
sponse and that bystander activation only plays a minimal role
in this context. Tetramer staining data exposed distinct effector
and memory CD8+ T cell phenotypes and also revealed that the
effector-to-memory transition is a gradual and linear process,
associated with multiple phenotypic changes. Taken together,
these results provide a benchmark for the CD8+ T cell response
induced by two highly successful human vaccines and provides
insight into human memory T cell differentiation after acute viral
infection.
EXPERIMENTAL PROCEDURES
Vaccine Immunizations
After receipt of informed consent, healthy volunteers were screened for ex-
pression of HLA-A2. Ten male and female healthy volunteers (ranging in age
from 21 to 32 years) found to be HLA-A2 positive were administered the
live-attenuated YFV-17D vaccine (YF-Vax, sanofi pasteur) or the live vaccinia
smallpox vaccine (Dryvax, Wyeth Laboratories) according to the product label.
YF-Vax was administered subcutaneously in the arm with no less than 4.74
log10 plaque-forming units per 0.5 ml dose. Dryvax was administered by scar-
ification in the upper arm with three pricks of a bifurcated needle (estimated
dose 2.5 3 105 PFU).
Study Subjects and Blood Samples
This study protocol was reviewed and approved by the Emory University
Human Investigations Committee. Volunteer screening, vaccination, and col-
lection of blood samples were done in close collaboration with the Hope Clinic
of the Emory Vaccine Center. Exclusion criteria for vaccination followed rec-
ommendations established by the Advisory Committee on Immunization Prac-
tices (ACIP) and the YF-Vax and Dryvax product labels. Blood samples were
obtained from the volunteers at baseline and at sequential times after vaccina-
tion. Samples were obtained at days 0, 3, 7, 11, 15, and 30 after YF-Vax immu-
nization or at days 0, 7, 14, 21, 28, and 84 after Dryvax immunization. Slightly
different schedules were employed for some donors, as indicated in the text.
Seroconversion after vaccination was confirmed by assaying of the neutraliz-
ing antibody titers for YFV-17D and VV (data not shown). PBMCs were purified
by Ficoll-Hypaque density gradient centrifugation of heparinized blood sam-
ples or with CPT tubes. EDTA blood samples were used to quantify viral RNA.
Reagents
All monoclonal antibodies were obtained from BD PharMingen (San Diego,
CA). HLA-A2 INFGIL, HLA-B8 EBVRAK, HLA-A2 EBVGLC, and HLA-A2 VVCLT tet-
ramers were made as previously described (Miller et al., 2003). The WR strain
of vaccinia virus was obtained from the ATCC. SW480 cells were obtained
from the ATCC, and the YFV-17D used for in vitro infection originated from
infectious transcripts made from the full-length complementary DNA (cDNA)
clone, as described previously (Rice et al., 1989).
Staining and Flow Cytometry
The appropriate antibodies were added to 150–500 ml whole blood and incu-
bated at room temperature for 30 min, and 10 min lysis of red blood cells
with FACS Lysing Solution (BD PharMingen) followed. For intracellular stain-
ing, cells were permeabilized with FACS Permeabilization solution (BD Phar-
Mingen) and incubated with antibodies against Bcl-2, Ki-67, granzyme B,
and perforin. Samples were analyzed on a FACScalibur flow cytometer (BD
PharMingen) and analyzed with Flowjo (Treestar, Ashland, OR) software.Immunity 28, 710–722, May 2008 ª2008 Elsevier Inc. 719
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The YFV-17D peptide synthesis and their organization into peptide pools were
done on the basis of methods described by Hoffmeister et al. (2003). The
library consisted of 15 amino acid long nonamidylated peptides (SynPep, Dub-
lin, CA) spanning the entire YFV-17D polyprotein; consecutive peptides over-
lapped by 11 amino acids. The 851 peptides comprising the library were orga-
nized into 60 pools based on a 243 30 matrix with each pool containing 24 to
30 peptides.
Yellow Fever Stimulation Assays
PBMCs were stimulated with either with peptide pools (with each peptide at
a concentration of 10 mg/ml) or SW-480 cells that had been infected with
YFV-17D (multiplicity of infection [m.o.i.] 1, used at 48 hr after infection) or
mock infected at a ratio of 1:1. For intracellular cytokine staining experiments,
500,000 PBMCs were incubated with 500,000 SW-480 cells for 6 hr in the pres-
ence of brefeldin A. After the incubation, cells were fixed with FACS lysing
solution (BD PharMingen), permeabilized (FACS Permeabilization solution,
BD PharMingen), and incubated with antibodies against CD3, CD8, IFN-g,
and TNF-a. Flow cytometry and analysis were performed as described above.
For the in vitro CFSE dilution assay, 1–23 107 PBMCs were labeled with 3 mM
CFSE for 5 min, washed, and resuspended in RPMI containing 10% fetal calf
serum (FCS). The labeled cells were stimulated in a 24-well plate with a pool of
five YFV-17D-specific peptides. Medium was replaced 3 days after culture,
and the CFSE dilution was analyzed by flow cytometry after a total
incubation of 6 days.
Vaccinia Virus Stimulation Assays
PBMCs were stimulated for 15 hr with live WR strain of vaccinia virus (ATCC,
Manassas, VA) at an m.o.i. of 1. After the 15 hr incubation at 37C, Brefeldin A
was added and the cultures were incubated for an additional 5 hr. The cells
were then stained for CD3 and CD8 surface antigens as described above. Cul-
tures were then fixed and permeabilized with a cytofix and cytoperm kit (BD
PharMingen) and stained for intracellular IFN-g and TNF-a. Flow cytometry
and analysis were performed as described above. In vitro proliferation with
CFSE dilution was done as described for YFV-17D with HLA-A2 VVCLT peptide
for stimulation instead of YFV-17D peptides.
YFV-Specific Real-Time PCR
YFV in the blood of vaccinees was obtained with a TaqMan real-time polymer-
ase chain reaction (PCR) assay (Applied Biosystems, Foster City, CA). The fol-
lowing primers were used: 50-CTACGTGTCTGGAGCCCGCAGCAAT-30 (FAM-
and TAMRA-labeled TaqMan probe), 50-GAACAGTGATCAGGAACCCTCTCT
-30 (Fwd primer), and 50-GGATGTTTGGTTCACAGTAAATGTG-30 (Rev primer).
Primers for real-time PCR were designed within the highly conserved non-
structural NS5 gene of YFV with Primer Express software (Applied Biosys-
tems). RNA was isolated from plasma samples with a QIAamp viral RNA minikit
(QIAGEN, Netherlands). The two-step reverse transcriptase (RT)-PCR was
performed with a TaqMan Gold kit under the following conditions: The 50 ml re-
actions contained 5 ml of 103 TaqMan buffer A, 4 mM MgCl2, 400 mM dNTPs,
a 200 nM concentration of each primer, a 125 nM concentration of the fluoro-
genic probe, 2.5 mM of random hexamer, 1.25 units of AmpliTaq Gold DNA
polymerase (Applied Biosystems), 20 units of recombinant Mo-MuLV Multi-
Scribe, and 8 units of RNase inhibitor in 20 ml volume for reverse transcription.
Thermal cycling conditions consisted of 10 min at 25C, 20 min at 42C, 5 min
at 99C (first step), 10 min at 95C, and then 45 cycles of 15 s at 95C and 1 min
at 60C. Absolute quantification of RNA transcripts was determined with RNA
template standards.
Detection of Neutralizing Antibodies
Serum-neutralizing antibody titers were determined as previously described
(Newman et al., 2003).
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